Lennox Gastaut Syndrome — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for lennox gastaut syndrome. 128 active patents protecting 6 drugs from 6+ originators. First major cliff: 2028. Daily refresh.

6
Approved drugs
128
Active US patents
62/100
Avg vulnerability
$800M
Annual revenue covered

Originators in Lennox Gastaut Syndrome

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Janssen 70 patents Jazz Pharms Res 32 patents GSK 8 patents Lundbeck Pharms Llc 7 patents Novartis AG (originally Geigy) 7 patents Generic (originally Wyeth/Pfizer) 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating lennox gastaut syndrome. Each bar = one year. Y-axis scaled to peak year (36 patents).

36
27
6
28
9
29
26
33
4
34
27
35
6
39
11
40
3
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Topamax
topiramate
 Janssen 70 66 — 2027-11-16
Epidiolex
CANNABIDIOL
 Jazz Pharms Res 32 48 $800M 2035-06-17
Lamictal
lamotrigine
 GSK 8 64 — 2029-01-07
Tegretol
carbamazepine
 Novartis AG (originally Geigy) 7 55 — 2028-11-10
Onfi
CLOBAZAM
 Lundbeck Pharms Llc 7 73 — 2039-09-05
Ativan
lorazepam
 Generic (originally Wyeth/Pfizer) 4 64 — 2034-01-08

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8663683 Topamax method of use 80 2027-11-16
8889191 Topamax method of use 80 2027-11-16
8298580 Topamax method of use 80 2027-11-16
8663683 Topamax method of use 80 2027-11-16
8877248 Topamax method of use 80 2027-11-16
8889191 Topamax method of use 80 2027-11-16
8298580 Topamax method of use 80 2027-11-16
8877248 Topamax method of use 80 2027-11-16
8663683 Topamax method of use 80 2027-11-16
8889191 Topamax method of use 80 2027-11-16

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10709673 Epidiolex formulation 25 2035-06-17
9101545 Topamax formulation 42 2033-03-19
9101545 Topamax formulation 42 2033-03-19
9555005 Topamax formulation 42 2033-03-19
9101545 Topamax formulation 42 2033-03-19
9101545 Topamax formulation 42 2033-03-19
9555005 Topamax formulation 42 2033-03-19
9555005 Topamax formulation 42 2033-03-19
9101545 Topamax formulation 42 2033-03-19
9555005 Topamax formulation 42 2033-03-19

Related